Peter Donnelly, PhD

CurriculumVitae
J Peter Donnelly PhD
Co-ordinator, Studies in Supportive Care
Department of Haematology
Radboud University Nijmegen Medical Center
PO Box 9101 6500 HB Nijmegen
The Netherlands
Tel: +31-24-361-9987
Fax: +31-24-354-2080
e-mail: p.donnelly@usa.net
June 2007
Date Signature
CV Donnelly
2
Summary
• BSc and PhD in Microbiology with international laboratory experience
• Regular speaker at international meetings on aspects of supportive care in cancer,
particularly with reference to mucosal barrier injury and all aspects of managing
fungal infections including diagnosis, treatment, new antifungal agents and
resistance in fungi
• Author of 110 research papers and reviews and 15 book chapters
• Extensive editorial experience as Associate Editor of Journal Antimicrobial
Chemotherapy (Citation index >4.0), section editor of the International Journal of
Infectious Diseases, reviewer for top peer-reviewed journals including the Lancet
(Citation index >8.0) and Clinical Infectious Diseases (Citation index >4.0)
• Experienced in the design, conduct, analysis and reporting of single centre and
multicentre clinical trials.
• Skilled in data registration and management and in statistical analysis.
• Broad network in medical mycology, haematology, and infection generally.
• Good grasp of methodology in microbiology and mycology and extensive teaching
experience
CV Donnelly
3
Personal details
Surname: Donnelly
Christian names: Joseph Peter
Date of Birth: 13th March 1951
Place of Birth: County Durham, England, United Kingdom
Nationality: British
Status: Married, 8 children
Residences
1951-1953 Spennymoor, County Durham, England
1953-1959 Milingavie, Strathclyde, Scotland
1959-1979 Glasgow, Scotland
1979-1987 Southall, London, England
1987-1989 Millingen aan de Rijn, The Netherlands
1989-1998 Zwanenveld, Nijmegen, The Netherlands
Presently Lindenholt, Nijmegen, The Netherlands
CV Donnelly
4
Education
Scottish leaving certificates
Secondary education: St Thomas Aquinas Secondary School, Glasgow
1969 Ordinary in Arithmetic, Mathematics, French, Latin.
Higher Ordinary in English B grade, Mathematics, Chemistry and
Physics each at C grade.
1970 B grade passes in Mathematics and Chemistry and C grade in
Physics
Degrees and Diplomas
1974 Graduated as a Bachelor of Science of the University of Glasgow
with Ordinary level Biology and History of Science, Higher
Ordinary level Physiology, Biochemistry and Microbiology and
Advanced Ordinary Genetics
1978 Graduated in Microbiology for Membership to the Institute of
Biology
1979 Graduated as a Fellow of the Institute of Medical Laboratory
Sciences
1993 Graduated to PhD with “Viridans streptococci and allogeneic
bone marrow transplant recipients”
Societies and affiliations
1970-73 President of the Catholic Society, University of Glasgow
CV Donnelly
5
1970-72 Member of Student Social Action, University of Glasgow
1975-79 Group representative/ branch committee member of the Association of
Scientific, Technical and Managerial Staff (Glasgow)
1975-79 Member of the Joint Shop Stewards' Committee (Glasgow)
1978-79 Health and Safety Representative for Microbiology Gartnavel General
Hospital
1978 - Fellow of the Institute of Medical Laboratory Sciences
1978 - Chartered Member of the Institute of Biology
1979 -87 Member of the Society of General Microbiology
1986 - Member of the British Society of Antimicrobial Chemotherapy
1987 - Member of the American Society of Microbiology
1987-91 Member of the EORTC Gnotobiotic Project Group
1988 - Member of the International Society on Infections in the
Immunocompromised Host
1993 - Member of European Society for Biomodulation and Chemotherapy
1992 - Member of the Multinational Association of Supportive Care in Cancer
1992 - Member of the MASSC/ISO Working party on Mucosal Barrier Injury
1998 - Member of the EBMT Infectious Disease Working Party
1999 - Member European Society of Clinical Microbiology and Infectious Diseases
1999 - Member European Confederation of Medical Mycology
CV Donnelly
6
2006 Member of the International Society for Human and Animal Mycology
CV Donnelly
7
Employment
Past
1969-70 Technician -junior
Department of Mycology, University of Glasgow
1975-76 Technician -junior
Department of Medical Microbiology, Gartnavel General Hospital, Glasgow
1976-78 Technician- State Registered
Department of Medical Microbiology, Gartnavel General Hospital, Glasgow
1978-79 Technician -Senior
Department of Medical Microbiology, Gartnavel General Hospital, Glasgow
1979-85 Scientific Officer
Department of Bacteriology, Royal Postgraduate Medical School,
Hammersmith Hospital, London
1985-87 Scientific Officer-Senior
Department of Bacteriology, Royal Postgraduate Medical School,
Hammersmith Hospital, London
1987-90 Medical Microbiologist
Medical Microbiology, University Hospital Nijmegen
1990-96 Medical Microbiologist
Department of Haematology, University Hospital Nijmegen
CV Donnelly
8
Current position
September
1996
Co-ordinator, Supportive Care Studies
Department of Haematology, Radboud University Nijmegen Medical Center
( formerly University Hospital St Radboud Nijmegen)
CV Donnelly
9
Teaching activities
1981-82 visiting lecturer
Harrow College of Education, London
Fellowship Examination for the Institute of Medical Laboratory Sciences
Topics:- “Bacteriology of the Immunocompromised Host”
“Computer assisted identification of Gram negative bacteria”
1982-87 visiting lecturer/centre organiser,
Paddington College of Education, London
Fellowship Examination for the Institute of Medical Laboratory Sciences
Higher National Certificate- Microbiology
Topics:- “The Gram-positive cocci”
“Enterobacteriaceae”
“Taxonomy and identification”
“Biochemical tests”
“Antibiotics- mode of action, assessment of activity, assays and use”
“Parasitology”
“Evaluation of tests and techniques”
“Use of statistics in microbiology”
“Safety and organisation of the clinical laboratory”
CV Donnelly
10
1985-87 lecturer,
Hammersmith Hospital, London
Diploma in Clinical Pathology- microbiology module
Topics:- “Blood cultures and their clinical significance”
“Growth and nutrition of micro-organisms”
“Antibiotic susceptibility testing”
“Antibiotics active against the bacterial cell wall”
“Mechanisms of antibiotic resistance”
2000 Medical Undergraduate Course Bone Marrow Transplantation “Infectious
complications”
2001 -
present
Medical Mycology course – Antimycotic therapy
Official activities
Secretary for the Antifungal Susceptibility Testing subcommittee of the European
Committee for Antimicrobial Susceptibility Testing (AFST-EUCAST)
Secretary for the EORTC/MSG Consensus on defining invasive fungal infections
Board of Directors, Nijmegen Centre for Infectious Diseases
Executive member of the EORTC Infectious Diseases group
Member of the Infectious Diseases Working Party of the EBMT
Chair, ISHAM Working Party “Towards a standard for Aspergillus PCR”
Journal activities
Reviewer
CV Donnelly
11
Annals of Hematology
Annals of Oncology
Antonie van Leeuwenhoek
Bone Marrow Transplantation
British Journal of Haematology
Cancer Investigation
Clinical Infectious Diseases
European Journal of Clinical Investigation
European Journal of Haematology
Hematologica
International Journal of Infectious Diseases
Journal of Clinical Microbiology
Journal of Antimicrobial Chemotherapy
Journal of Infectious Diseases
Journal of Molecular Diagnostics
Lancet Infectious Disease
Leukaemia
Medical Mycology
Mycoses
Supportive Care in Cancer
The Lancet
Advisory Board
Journal of Antimicrobial Chemotherapy
Editorship
Journal of Antimicrobial Chemotherapy
International Journal of Infectious DIseases
CV Donnelly
12
Consultancies
None
CV Donnelly
13
Clinical trials
1 Co-trimoxazole versus co-trimoxazole
plus FRACON as prophylaxis of bacterial
infection in neutropenic patients with
acute leukaemia
Starke ID, Donnelly JP, Catovsky D, Darrell JH,
Goldman JM, Galton DAG. Lancet 1982;i:5-6.
2 Oral ketoconazole and amphotericin B
for prophylaxis in neutropenic patients
with acute leukaemia
Donnelly JP, Starke ID, Galton DAG, Catovsky D,
Goldman JM, Darrell JH. J Hosp Infect 1984;5:83-91.
3 Ceftazidime versus therapy for the
empirical treatment of fever in
neutropenic patients with acute
leukaemia
Donnelly JP, Worsley AM, Marcus RE, et al. J Infect
1985;11:205-215.
4 Ciprofloxacin for the prevention of
infection in neutropenic allogeneic BMT
recipients
De Pauw B E, Donnelly J P, DeWitte T, Nováková I R
O, Schattenberg A. Bone Marrow Transplant.
1990;5:179-182.
5 Co-trimoxazole-colistin versus
ciprofloxacin for the prevention of
infection in neutropenic patients
Donnelly J P, Daenen S, Masschmeyer G. Eur J
Cancer. 1992;28A:873-878.
6 Flemoxacillin versus placebo for the
prevention of viridans streptococcal
bacteraemia in BMT recipients
7 Double, blind study of itraconazole
capsules versus amphotericin B for the
prevention of fungal infection
Vreugdenhill G, Van Dijk B, Novakova IRO,
Donnelly JP, Raemaekers JMM, Hoogkamp-
Korstanje JAA, Koster M, De Pauw BE Leuk
Lymphoma, 1993, 11;353-358
8 Double, blind study of itraconazole
suspension versus amphotericin B for
the prevention of fungal infection
Harousseau, J. L., Dekker, A. W., Stamatoullas-
Bastard, A., Fassas, A., Linkesch, W., Gouveia, J., et
al. (2000). Itraconazole oral solution for primary
prophylaxis of fungal infections in patients with
hematological malignancy and profound
neutropenia: a randomized, double-blind, doubleplacebo,
multicenter trial comparing itraconazole and
amphotericin B. Antimicrob Agents Chemother
44:1887-93.
9 Ceftazidime ± amikacin as empirical
therapy of the febrile neutropenic
patient with focal infection
Nováková I R O, Donnelly J P, De Pauw B E. Ann
Hematol. 1991;63:195-200.
10 Ceftazidime versus piperacillin +
amikacin as empirical therapy of the
febrile neutropenic patient
Nováková I R O, Donnelly J P, De Pauw B E. Scand J
Infect Dis. 1990;22:705-711.
11 Failures of ceftazidime as empirical
therapy of the febrile neutropenic
patient rescued by teicoplanin
Nováková I R O, Donnelly J P, De Pauw B E,
Verhagen C. J Antimicrob Chemother. 1990;25:985-
993.
CV Donnelly
14
12 Ceftazidime ± teicoplanin as empirical
therapy of the febrile neutropenic
patient
Nováková I R O, Donnelly J P, De Pauw B E. .
Antimicrob Ag Chemother. 1991;35:672-678.
13 Ceftazidime versus piperacillin +
tobramycin as empirical therapy of the
febrile neutropenic patient
De Pauw BE, Deresinski SC, Feld R, Lane Allman EF,
Donnelly JP. Ann Intern Med 1994;120(10):834-
844.
14 Ceftazidime versus ciprofloxacin as
empirical therapy of the low-risk febrile
neutropenic patient
15 Ceftazidime + clindamycin as empirical
therapy of the febrile neutropenic
patient allogeneic BMT recipient
Donnelly J P, Muus P, Horrevorts A M, Sauerwein R
W, De Pauw B E Scand J Infect Dis. 1993;25:43-50.
16 Cefepime as empirical therapy of the
febrile neutropenic allogeneic BMT
recipient
17 Ceftazidime versus meropenem as
empirical therapy of the febrile
neutropenic patient
Boogaerts MA, Demuynck H, Mestdagh N, Verbist, L,
Goldstone AH, Kelsey HC, Machin S, De Pauw BE,
Donnelly JP, Raemaekers JMM J Antimicrob
Chemother. 1995; 36;185-200
18 Ceftazidime versus meropenem as
empirical therapy of the febrile
neutropenic patient
Feld, R., DePauw, B., Berman, S., Keating, A.& Ho,
W. (2000). Meropenem versus ceftazidime in the
treatment of cancer patients with febrile
neutropenia: A randomized, double-blind trial. J Clin
Oncol 18:3690-8.
19 Ceftazidime plus either teicoplanin or
vancomycin for treating Gram-positive
bacterial infections in febrile
neutropenic patients
20 Ceftazidime intermittent or continuous
infusion as empirical therapy of the
febrile neutropenic patient
21 Tazobactam-piperacillin as empirical
therapy of the febrile neutropenic
patient with and without mucositis
22 Ceftazidime intermittent or continuous
infusion as empirical therapy of the
febrile neutropenic patient
23 Meropenem for pre-emptive treatment
of infection in BMT patients
24 Cefpirome versus ceftazidime as
empirical therapy of the febrile
neutropenic patient
CV Donnelly
15
25 Amphotericin B ± 5-flucytosine for the
treatment of proven systemic mycoses
in neutropenic patients
Verweij PE, Donnelly JP, Kullberg BJ, Meis JF, De-
Pauw BE. Infection 1994;22(2):81-85.
26 Fluconazole for the treatment of
candidiasis
De Pauw BE, Raemaekers JMM, Donnelly JP,
Kullberg BJ, Meis JFGM. Ann Hematol 1995;70:83-
87.
27 An EORTC international multicenter
randomized trial (EORTC number
19923) comparing two dosages of
liposomal amphotericin B for treatment
of invasive aspergillosis
Ellis M, Spence D, de Pauw B, et al. Clin Infect Dis
1998;27:1406-12.
28 UK 109,496 for presumptive
aspergillosis, open, phase II study
Denning DW, Ribaud P, Milpied N, et al. Efficacy and
safety of voriconazole in the treatment of acute
invasive aspergillosis. Clin Infect Dis
2002;34(5):563-71.
29 High-dose fluconazole therapy in
patients with severe fungal infections
Voss A, de Pauw BE. Eur J Clin Microbiol Infect Dis
1999;18:165-74.
30 Amphotericin B with and without
terbinafine for treating pulmonary
aspergillosis in neutropenic patients
31 Amphotericin B versus voriconazole for
treating pulmonary aspergillosis in
neutropenic patients
Herbrecht R, Denning DW, Patterson TF, Bennett JE,
Greene RE, Oestmann JW, et al. Voriconazole versus
amphotericin B for primary therapy of invasive
aspergillosis. N Engl J Med 2002;347(6):408-15.
32 Liposomal nystatin for treating
pulmonary aspergillosis in neutropenic
patients
33 Metabisulfite for disinfecting indwelling
central venous catheters
34 Glutamine dipeptide-supplemented total
parenteral nutrition in allogeneic
haematopoietic stem cell transplant
recipients
Blijlevens NM, Donnelly JP, Naber AH,
Schattenberg AV, Depauw BE. A randomised,
double-blinded, placebo-controlled, pilot study of
parenteral glutamine for allogeneic stem cell
transplant patients. Support Care Cancer 2005.
35 Pharmacokinetics of intraconazole
nanocrystals in allogeneic
haematopoietic stem cell transplant
recipients
36 IB-367 for the prevention of oral
mucositis in patients who are
undergoing myeloablative conditioning
regimens
CV Donnelly
16
37 Investigation of the effect of a small
volume nutritional supplement on
mucosal barrier injury associated with
intensive cytotoxic therapy: a
prospective, randomised, double-blind,
clinical exploratory study
38 An investigation into the relationship
between the presence of periodontitis
and the occurrence of oral mucositis
before conditioning for a
haematopoietic stem cell transplant.
39 A Strategic Study to Determine the
Optimal Moment to Initiate Systemic
Antifungal Therapy with AmBisome® in
Granulocytopenic Cancer Patients with
Unexplained Fever Refractory to
Empirical Antibacterials
40 An open study of intravenous
itraconazole for invasive fungal
infectious diseases
41 Pharmacokinetics and safety of 2
different routes of intravenous
cyclosporin administration in allogeneic
haematopoietic stem cell transplant
recipients; with emphasis on the role of
gut mucositis
Hendriks MP, Blijlevens NM, Schattenberg AV, Burger
DM, Donnelly JP. Cyclosporine short infusion and
C2 monitoring in haematopoietic stem cell transplant
recipients. Bone Marrow Transplant 2006;38(7):521-
5.
42 Pharmacokinetics and safety of 14 days
intravenous treatment with
voriconazole for antifungal prophylaxis
of recipients of an allogeneic
haematopoietic stem cell transplant
(HSCT).
43 A feasibility study of enteral nasogastric
tube feeding in patients treated for AML
or MDS with intensive chemotherapy
44 Pharmacokinetics and safety of 15 days
intravenous treatment with caspofungin
for antifungal prophylaxis of recipients
of an autologous haematopoietic stem
cell transplant (HSCT).
CV Donnelly
17
45 A Phase 3b, Multi-Center, Randomized,
Double Blind Study of the Safety and
Efficacy of an AmBisome® Loading
Dose Regimen Versus a Standard
AmBisome® Regimen for the Initial
Treatment of Invasive Aspergillosis and
Other Filamentous Fungal Infections in
Immunocompromised Patients
46 A Multicenter, Open, Phase II Study to
Estimate the activity and safety of
Caspofungin (CASP) in the Firstline
Treatment of probable and proven
Invasive Aspergillosis (IA) in Patients
with Hematological Malignances (HM)
or recipients of autologous
Haematopoietic Stem Cell
Transplantation and those with
allogeneic Haematopoietic Stem Cell
Transplantation (HSCT)
47 CB24 Linezolid for treating
haematopoietic stem cell transplant
recipients with persistent bacteraemia
due to Staphylococcus epidermidis
48 Identification of febrile neutropenic
patients at risk to develop an invasive
fungal infection : a multinational
observational study in selected cancer
patients
49 Safety and efficacy of human lactoferrin
hLF1-11 for the treatment of infectious
complications among haematopoietic
stem cell transplant recipients - single
dose
50 Safety and efficacy of human lactoferrin
hLF1-11 for the treatment of infectious
complications among haematopoietic
stem cell transplant recipients - multiple
dose
51 Safety and efficacy of human lactoferrin
hLF1-11 for the treatment of infectious
complications among haematopoietic
stem cell transplant recipients - proof of
concept
CV Donnelly
18
52 Safety and efficacy of human lactoferrin
hLF1-11 for the treatment of infectious
complications among haematopoietic
stem cell transplant recipients - RCT
CV Donnelly
19
Publications
Articles
1. Donnelly JP, editor. Serum bactericidal levels in leukaemic patients treated with either
netilmicin or tobramycin in combination with mezlocillin and cefuroxime; 1982.
2. Starke ID, Donnelly P, Catovsky D, Darrell J, Johnson SA, Goldman JM, et al. Co-trimoxazole
alone for prevention of bacterial infection in patients with acute leukaemia. Lancet
1982;1(8262):5-6.
3. Cohen J, Donnelly JP, Worsley AM, Catovsky D, Goldman JM, Galton DA. Septicaemia caused
by viridans streptococci in neutropenic patients with leukaemia. Lancet 1983;2 (8365-
66):1452-4.
4. Donnelly JP, Starke ID, Galton DA, Catovsky D, Goldman JM, Darrell JH. Oral ketoconazole
and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia. J
Hosp Infect 1984;5(1):83-91.
5. Rowe IF, Worsley AM, Donnelly P, Catovsky D, Goldman JM, Galton D, et al. Measurement of
serum C reactive protein concentration after bone marrow transplantation for leukaemia. J Clin
Pathol 1984;37(3):263-6.
6. Starke ID, de Beer FC, Donnelly JP, Catovsky D, Goldman JM, Galton DA, et al. Serum Creactive
protein levels in the management of infection in acute leukaemia. Eur J Cancer Clin
Oncol 1984;20(3):319-25.
7. Donnelly JP. Interpretation of disc diffusion susceptibility tests: a comparison of methods.
Med Lab Sci 1985;42(2):148-55.
8. Donnelly JP. Ceftazidime alone versus a combinaton of piperacillin, cefotaxime and netilmicin
for the empirical therapy of infection in patients with acute leukaemia. Insights Treat Ser Infect
1985;1: 133-7.
9. Donnelly JP, Cohen J, Marcus R, Guest J. Bacteraemia and Hickman catheters. Lancet
1985;2(8445):48.
10. Donnelly JP, Marcus RE, Goldman JM, Cohen J, Worsley AM, Catovsky D, et al. Ceftazidime
as first-line therapy for fever in acute leukaemia. J Infect 1985;11(3):205-15.
11. Smith J, Hows G, Donnelly JP, Baugham A, Goldman JM, Gordon-Smith EC. Interaction of
cyclosporin A and ketoconazole. Exp Haematol 1985;11(suppl 13):176-8.
12. Donnelly JP. Ceftazidime as monotherapy for infection in the neutropenic patients. Res Clin
For 1986;8(3):47-54.
13. Donnelly JP. Comparison of methods for the interpretation of disk diffusion susceptibility
tests for augmentin. Diagn Microbiol Infect Dis 1986;5(3):255-63.
14. Verhagen C, de Pauw BE, Donnelly JP, Williams KJ, de Witte T, Janssen TH. Ceftazidime
alone for treating Pseudomonas aeruginosa septicaemia in neutropenic patients. J Infect
1986;13(2):125-31.
15. Novakova I, Donnelly P, de Witte T, de Pauw B, Boezeman J, Veltman G. Itraconazole and
cyclosporin nephrotoxicity. Lancet 1987;2(8564):920-1.
16. Schattenberg A, De Vries F, De Witte T, Cohen O, Donnelly JP, De Pauw BE. Allogeneic bone
CV Donnelly
20
marrow transplantation after partial lobectomy for aspergillosis of the lung. Bone Marrow
Transplant 1988;3(5):509-12.
17. De Pauw BE, Donnelly JP, Harding I. Clinical experience with teicoplanin in patients with
intravascular line infection due to Gram-positive bacteria. In: Phillips I, editor. Focus on
coagulase-negative staphylococci. London: Royal Society of Medicine; 1989. p. 107-18.
18. De Pauw BE, Nováková IRO, Donnelly JP, Horrevorts A. Mono- of combinatietherapie bij
ernstige bacteriële infecties? [Mono or combination therapy in severe bacterial infections?].
Ned.T.Geneesk. 1989;133([letter]):954-5.
19. Weers-Pothoff G, Novakova IR, Donnelly JP, Muytjens HL. Bacteraemia caused by
Stomatococcus mucilaginosus in a granulocytopenic patient with acute lymphocytic leukaemia.
Neth J Med 1989;35(3-4):143-6.
20. De Pauw BE, Donnelly JP, De Witte T, Novakova IR, Schattenberg A. Options and limitations
of long-term oral ciprofloxacin as antibacterial prophylaxis in allogeneic bone marrow
transplant recipients. Bone Marrow Transplant 1990;5(3):179-82.
21. De Pauw BE, Donnelly JP, Elves A, Verhagen C, Novakova IR, Van der Meer JW. Towards
individually tailored empiric antibiotic therapy in febrile granulocytopenic patients. Neth J Med
1990;37(3-4):111-9.
22. De Pauw BE, Novakova IR, Donnelly JP. Options and limitations of teicoplanin in febrile
granulocytopenic patients. Br J Haematol 1990;76 Suppl 2:1-5.
23. Maschmeyer G, Daenen S, de Pauw BE, de Vries-Hospers HG, Dekker AW, Donnelly JP, et al.
Prevention of infection in acute leukemia. Hamatol Bluttransfus 1990;33:525-30.
24. Novakova I, Donnelly P, De Pauw B. Amikacin plus piperacillin versus ceftazidime as initial
therapy in granulocytopenic patients with presumed bacteremia. Scand J Infect Dis
1990;22(6):705-11.
25. Novakova IR, Donnelly JP, Verhagen CS, De Pauw BE. Teicoplanin as modification of initial
empirical therapy in febrile granulocytopenic patients. J Antimicrob Chemother
1990;25(6):985-93.
26. Donnelly JP. Colistin. In: Dollery CT, editor. Therapeutic Drugs. Edinburgh, London,
Melbourne, New York, Tokyo and Madrid: Churchill Livingstone; 1991.
27. Donnelly JP. Assessment and reporting of clinical trials of empirical therapy in neutropenic
patients. J Antimicrob Chemother 1991;27(3):377-87.
28. Novakova I, Donnelly JP, De Pauw B. Ceftazidime as monotherapy or combined with
teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic
patients. Antimicrob Agents Chemother 1991;35(4):672-8.
29. Novakova IR, Donnelly JP, de Pauw BE. Ceftazidime with or without amikacin for the empiric
treatment of localized infections in febrile, granulocytopenic patients. Ann Hematol
1991;63(4):195-200.
30. Denning DW, Donnelly JP, Hellreigel KP, Ito J, Martino P, van't Wout JW. Antifungal
prophylaxis during neutropenia or allogeneic bone marrow transplantation: what is the state of
the art? Ad HOC Working Group. Chemotherapy 1992;38 Suppl 1:43-9.
31. Donnelly JP. Describing and comparing in-vitro antimicrobial activity by the box-plot
technique. J Antimicrob Chemother 1992;30(5):713-9.
CV Donnelly
21
32. Donnelly JP, De Pauw BE. Diagnosis and treatment of infection in the immunocompromised
host. Current Opinions in Infectious Diseases 1992;5:415-21.
33. Donnelly JP, Horrevorts AM, Sauerwein RW, De Pauw BE. High-dose meropenem in
meningitis due to Pseudomonas aeruginosa. Lancet 1992;339(8801):1117.
34. Donnelly JP, Maschmeyer G, Daenen S. Selective oral antimicrobial prophylaxis for the
prevention of infection in acute leukaemia-ciprofloxacin versus co-trimoxazole plus colistin. The
EORTC-Gnotobiotic Project Group. Eur J Cancer 1992:873-8.
35. Donnelly JP, Muus P, Schattenberg A, De Witte T, Horrevorts A, DePauw BE. A scheme for
daily monitoring of oral mucositis in allogeneic BMT recipients. Bone Marrow Transplant
1992;9(6):409-13.
36. Donnelly JP, Willemse JG, Horrevorts AM, De Pauw BE. The activity of meropenem,
ceftazidime and other antibiotics against bacteremic isolates from granulocytopenic and other
patients. Span J Chemother 1992;5(suppl 4):65-71.
37. Muus P, De Witte T, Schattenberg A, Donnelly JP, Hoogenhout J. Intensification of the
conditioning regimen for allogeneic bone marrow transplantation in recipients of T-cell
depleted grafts by the addition of anthracyclines. Leuk Lymphoma 1992;7(suppl 2):11-4.
38. De Witte T, Van Der Lely N, Muus P, Donnelly JP, Schattenberg T. Recombinant human
granulocyte macrophage colony stimulating factor (rhGM-CSF) accelerates bone marrow
recovery after allogeneic T-cell depleted bone marrow transplantation. L'Ospedale Maggiore
1993;87(1):42-6.
39. Donnelly JP. Selective decontamination of the digestive tract and its role in antimicrobial
prophylaxis. J Antimicrob Chemother 1993;31(6):813-29.
40. Donnelly JP, Muus P, Horrevorts AM, Sauerwein RW, De Pauw BE. Failure of clindamycin to
influence the course of severe oromucositis associated with streptococcal bacteraemia in
allogeneic bone marrow transplant recipients. Scand J Infect Dis 1993;25(1):43-50.
41. Donnelly JP, Novakova IR, Raemaekers JM, De Pauw BE. Empiric treatment of localized
infections in the febrile neutropenic patient with monotherapy. Leuk Lymphoma
1993;9(3):193-203.
42. Meis JF, Donnelly JP, Hoogkamp-Korstanje JA, De Pauw BE. Aspergillus fumigatus
pneumonia in neutropenic patients during therapy with fluconazole for infection due to
Candida species. Clin Infect Dis 1993;16(letter):734-5.
43. Muus P, Donnelly P, Schattenberg A, Linssen P, Minderman H, Dompeling E, et al. Idarubicinrelated
side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are
schedule dependent. Semin Oncol 1993;20(6 Suppl 8):47-52.
44. Novakova IR, Donnelly JP, De Pauw B. Potential sites of infection that develop in febrile
neutropenic patients. Leuk Lymphoma 1993;10(6):461-7.
45. Vreugdenhil G, Van Dijke BJ, Donnelly JP, Novakova IR, Raemaekers JM, Hoogkamp-
Korstanje MA, et al. Efficacy of itraconazole in the prevention of fungal infections among
neutropenic patients with hematologic malignancies and intensive chemotherapy. A double
blind, placebo controlled study. Leuk Lymphoma 1993;11(5-6):353-8.
46. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime compared with
piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with
cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann
CV Donnelly
22
Intern Med 1994;120(10):834-44.
47. Dompeling EC, Donnelly JP, Raemaekers JM, De Pauw BE. Pre-emptive administration of
corticosteroids prevents the development of ARDS associated with Streptococcus mitis
bacteremia following chemotherapy with high-dose cytarabine. Ann Hematol 1994;69(2):69-
71.
48. Donnelly JP. Limitations of box-plots in summarizing MIC data. J Antimicrob Chemother
1994;33(letter):1251-2.
49. Donnelly JP, De Pauw BE. Current infectious complications and their management in acute
leukaemia and bone marrow transplantation. Int J Antimicrob Ag 1994;3:245-50.
50. Maschmeyer G, Donnelly JP, Krcmery Jr. V. Infections in neutropenic cancer patients - a new
multinational study group has been initiated by the ESBiC. Antiinfective Drugs and
Chemotherapy 1994;12(1):5-8.
51. Meis JF, Donnelly JP, Hoogkampkorstanje JA, De Pauw BE. Aspergillus fumigatus pneumonia
in neutropenic patients receiving fluconazole for infection due to candida species - is
amphotericin b combined with fluconazole the appropriate answer - reply. Clinical Infectious
Diseases 1994;18:485-6.
52. Verweij PE, Donnelly JP, Kullberg BJ, Meis JF, De Pauw BE. Amphotericin B versus
amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in
neutropenic patients. Infection 1994;22(2):81-5.
53. Boogaerts MA, Demuynck H, Mestdagh N, Verbist L, Goldstone AH, Kelsey HC, et al. Equivalent
efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic
patients. Journal of Antimicrobial Chemotherapy 1995;36(1):185-200.
54. de Pauw BE, Donnelly JP, Raemaekers JM, Hoogkamp-Korstanje JA. [Rational use of
antibiotics in the neutropenic patient with fever] Rationeel gebruik van antibiotica bij de
neutropenische patiënt met koorts. Ned Tijdschr Geneeskd 1995;139(34):1725-9.
55. De Pauw BE, Raemaekers JM, Donnelly JP, Kullberg BJ, Meis JF. An open study on the safety
and efficacy of fluconazole in the treatment of disseminated Candida infections in patients
treated for hematological malignancy. Ann Hematol 1995;70(2):83-7.
56. Donnelly JP. Chemoprophylaxis for the prevention of bacterial and fungal infections. In:
Klastersky J, editor. Infectious complications of cancer. Boston, Dordrecht, London: Kluwer
Academic Publishers; 1995. p. 45-81.
57. Donnelly JP. Bacterial complications of transplantation: diagnosis and treatment. J Antimicrob
Chemother 1995;36:59-72.
58. Donnelly JP. Chemoprophylaxis for the prevention of bacterial and fungal infections. Cancer
Treat Res 1995;79:45-81.
59. Donnelly JP, Dompeling EC, Meis JF, de Pauw BE. Bacteremia due to oral viridans
streptococci in neutropenic patients with cancer: cytostatics are a more important risk factor
than antibacterial prophylaxis. Clin Infect Dis 1995;20(2):469-70.
60. Dompeling EC, Donnelly JP, Deresinski SC, Feld R, Lane-Allman EF, De Pauw BE. Early
identification of neutropenic patients at risk of grampositive bacteraemia and the impact of
empirical administration of vancomycin. Eur J Cancer 1996;32A(8):1332-9.
61. Donnelly JP, Voss A, Witte W, Murray BE. Does the use in animals of antimicrobial agents,
including glycopeptide antibiotics, influence the efficacy of antimicrobial therapy in humans.
CV Donnelly
23
Journal Of Antimicrobial Chemotherapy 1996;37(2):389-90.
62. Verweij PE, Donnelly JP, De Pauw BE, Meis JF. Aspergillus infections: problems in diagnosis
and treatment. Infect Agents Dis 1996;5(4):245-6.
63. Verweij PE, Donnelly JP, De Pauw BE, Meis JFGM. Prospects for the early diagnosis of
invasive aspergillois in the immunocompromised host. Rev Med Microbiol 1996;7(2):105-13.
64. Verweij PE, Donnelly JP, Meis JF. High-dose itraconazole for the treatment of cerebral
aspergillosis. Clin Infect Dis 1996;23(5):1196-7.
65. Daemen HJG, Burger DM, Heckster YA, Donnelly JP. Meropenem (Meronem®).
Pharmaceutisch Weekblad 1997;132(32):1166-71.
66. De Pauw BE, Donnelly JP. Controversies in the antibacterial treatment of patients with
neutropenia: a matter of comprehension or apprehension? Cancer Invest 1997;15(1):37-46.
67. De Pauw BE, Raemaekers JM, Schattenberg T, Donnelly JP. Empirical and subsequent use of
antibacterial agents in the febrile neutropenic patient. J Intern Med Suppl 1997;740:69-77.
68. Donnelly JP. Is there a rationale for the use of antimicrobial prophylaxis in neutropenic
patients? J Intern Med Suppl 1997;740:79-88.
69. Pouwels MJ, Donnelly JP, Raemaekers JM, Verweij PE, de Pauw BE. Clostridium septicum
sepsis and neutropenic enterocolitis in a patient treated with intensive chemotherapy for acute
myeloid leukemia. Ann Hematol 1997;74(3):143-7.
70. Severens JL, Donnelly JP, Meis JF, De Vries Robbe PF, De Pauw BE, Verweij PE. Two
strategies for managing invasive aspergillosis: a decision analysis. Clin Infect Dis
1997;25(5):1148-54.
71. Swanink CM, Meis JF, Rijs AJ, Donnelly JP, Verweij PE. Specificity of a sandwich enzymelinked
immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol
1997;35(1):257-60.
72. Verweij PE, Dompeling EC, Donnelly JP, Schattenberg AV, Meis JF. Serial monitoring of
Aspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations
with two examples. Infection 1997;25(2):86-9.
73. Verweij PE, Voss A, Donnelly JP, de Pauw BE, Meis JF. Wooden sticks as the source of a
pseudoepidemic of infection with Rhizopus microsporus var. rhizopodiformis among
immunocompromised patients. J Clin Microbiol 1997;35(9):2422-3.
74. De Pauw BE, Donnelly JP, Kullberg BJ. Host impairments in patients with neoplastic diseases.
In: Noskin GA, editor. Management of infectious complication in cancer patients. Boston:
Kluwer Academic Publishers; 1998. p. 1-32.
75. Dompeling EC, Donnelly JP, Raemaekers JM, Deresinski SC, Feld R, De Pauw BE. Evolution of
the clinical manifestations of infection during the course of febrile neutropenia in patients with
malignancy. Infection 1998;26(6):349-54.
76. Donnelly JP. Miconazole. In: Dollery CT, editor. Therapeutic Drugs. 2 nd ed. Edinburgh,
London, Melbourne, New York, Tokyo and Madrid: Churchill Livingstone; 1998.
77. Verweij PE, Mensink M, Rijs AJ, Donnelly JP, Meis JF, Denning DW. In-vitro activities of
amphotericin B, itraconazole and voriconazole against 150 clinical and environmental
Aspergillus fumigatus isolates. J Antimicrob Chemother 1998;42(3):389-92.
78. Buchheidt D, Hiddemann W, Schiel X, Kremery V, Karthaus M, Donnelly JP, et al. European
CV Donnelly
24
surveillance of infections and risk factors in cancer patients. Eur J Clin Microbiol Infect Dis
1999;18(2):161-3.
79. De Pauw BE, Donnelly JP, Kullberg BJ. Treatment of fungal infections in surgical patients
using conventional antifungals. J Chemother 1999;11(6):494-503.
80. Donnelly JP. Commentary on the MAFF technical report: a review of antimicrobial resistance
in the food chain. Ministry of Agriculture Fisheries and Food. Int J Antimicrob Agents
1999;12(1):63-5.
81. Karthaus M, Buchheidt D, Hiddemann W, Donnelly JP, Krcmery V, Schiel X, et al. European
Surveillance of Infections in Cancer Patients--ESIC. Chemotherapy 1999;45(4):237-41.
82. Blijlevens NM, Donnelly JP, De Pauw BE. Mucosal barrier injury: biology, pathology, clinical
counterparts and consequences of intensive treatment for haematological malignancy: an
overview. Bone Marrow Transplant 2000;25(12):1269-78.
83. Blijlevens NM, Donnelly JP, Meis JF, De Keizer MH, De Pauw BE. Procalcitonin does not
discriminate infection from inflammation after allogeneic bone marrow transplantation. Clin
Diagn Lab Immunol 2000;7(6):889-92.
84. De Pauw BE, Donnelly JP. Infections in the Immunocompromised Host: General Principles.
In: Mandell GL, Douglas RG, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's
principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000.
p. 3079-90.
85. Donnelly JP. Febrile neutropenia: antifungal prophylaxis. Int J Antimicrob Agents
2000;16(2):127-30.
86. Donnelly JP. Infection in the neutropenic and haematopoietic stem cell transplant recipient.
Curr Opin Infect Dis 2000;13(4):337-42.
87. Donnelly JP. A strategy for managing fungal infections in haematopoietic stem cell
transplantation. Transpl Infect Dis 2000;2(2):88-95.
88. Meletiadis J, Meis JF, Mouton JW, Donnelly JP, Verweij PE. Comparison of NCCLS and 3-(4,5-
dimethyl-2-Thiazyl)-2, 5-diphenyl-2H- tetrazolium bromide (MTT) methods of in vitro
susceptibility testing of filamentous fungi and development of a new simplified method. J Clin
Microbiol 2000;38(8):2949-54.
89. van Assen S, Bootsma GP, Verweij PE, Donnelly JP, Raemakers JM. Aspergillus
tracheobronchitis after allogeneic bone marrow transplantation. Bone Marrow Transplant
2000;26(10):1131-2.
90. Ascioglu S, de Pauw BE, Donnelly JP, Collette L. Reliability of clinical research on invasive
fungal infections: a systematic review of the literature. Med Mycol 2001;39(1):35-40.
91. Blijlevens NM, Donnelly JP, de Pauw BE. Empirical therapy of febrile neutropenic patients
with mucositis: challenge of risk-based therapy. Clin Microbiol Infect 2001;7 Suppl 4:47-52.
92. Donnelly JP. Infection in bone marrow transplant patients. In: Thiru S, Waldmaan H, editors.
Pathology and Immunology of transplantation and Rejection. Oxford: Blackwell Science Ltd;
2001. p. 526-66.
93. Donnelly JP. Prophylaxis of infections. In: Rolston KVI, Rubenstein EB, editors. Textbook of
febrile nutropenia. London: Martin Dunnitz Ltd; 2001. p. 215-43.
94. Donnelly JP. Future perspectives in management of systemic fungal infection: review of
CV Donnelly
25
recent, ongoing and planned trials and the need for a national survveillance and audit of
infection. In: Prentice AG, Rogers T, Miles A, editors. The effective prevention and
management of systemic fungal infection in haematological malignancy. London, San
Francisco, Sydney: Aesculapius Medical Press; 2001. p. 133-49.
95. Donnelly JP, De Pauw BE, Lane Allman EF. Regional variations in the further management of
neutropenic patients already receiving empirical antimicrobial therapy. Hematology
2001;5:413-20.
96. Meletiadis J, Mouton JW, Meis JF, Bouman BA, Donnelly JP, Verweij PE. Colorimetric assay
for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2001;39(9):3402-8.
97. Meletiadis J, Mouton JW, Meis JF, Bouman BA, Donnelly PJ, Verweij PE. Comparison of
spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric
method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-
[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of
Aspergillus species. J Clin Microbiol 2001;39(12):4256-63.
98. Prentice AG, Donnelly P. Oral antifungals as prophylaxis in haematological malignancy. Blood
Rev 2001;15(1):1-8.
99. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic
invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem
cell transplants: an international consensus. Clin Infect Dis 2002;34(1):7-14.
100. Blijlevens NM, Donnelly JP, de Pauw BE. Impaired gut function as risk factor for invasive
candidiasis in neutropenic patients. Br J Haematol 2002;117(2):259-64.
101. Blijlevens NM, Donnelly JP, Meis JF, Verweij PE, de Pauw BE. Aspergillus galactomannan
antigen levels in allogeneic haematopoietic stem cell transplant recipients given total
parenteral nutrition. Transpl Infect Dis 2002;4(2):64-5.
102. Donnelly JP. Symptoms and diagnosis of nosocomial fungal infections -- state-of-the-art.
Eur J Med Res 2002;7(5):192-9.
103. Meletiadis J, Meis JF, Mouton JW, Rodriquez-Tudela JL, Donnelly JP, Verweij PE. In vitro
activities of new and conventional antifungal agents against clinical Scedosporium isolates.
Antimicrob Agents Chemother 2002;46(1):62-8.
104. Cuenca-Estrella M, Moore CB, Barchiesi F, Bille J, Chryssanthou E, Denning DW, et al.
Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing
method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the
European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol
Infect 2003;9(6):467-74.
105. Donnelly JP, Blijlevens NM, Verhagen CA. Can anything be done about oral mucositis? Ann
Oncol 2003;14(4):505-7.
106. Donnelly JP, Bellm LA, Epstein JB, Sonis ST, Symonds RP. Antimicrobial therapy to
prevent or treat oral mucositis. Lancet Infect Dis 2003;3(7):405-12.
107. Donnelly JP, Blijlevens NM, Schattenberg AV. Monitoring cyclosporine using blood drawn
via a central venous catheter. Bone Marrow Transplant 2003;32(10):1037.
108. Oude Lashof AM, Donnelly JP, Meis JF, Van Der Meer JW, Kullberg BJ. Duration of
antifungal treatment and development of delayed complications in patients with candidaemia.
Eur J Clin Microbiol Infect Dis 2003;22(1):43-8.
CV Donnelly
26
109. Rodriguez-Tudela JL, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M, Denning D, et
al. Method for the determination of minimum inhibitory concentration (MIC) by broth dilution
of fermentative yeasts. Clin Microbiol Infect 2003;9(8):I-VIII.
110. Van't Land B, Blijlevens NM, Marteijn J, Timal S, Donnelly JP, De Witte TJ, et al. Role of
curcumin and the inhibition of NF-kappaB in the onset of chemotherapy-induced mucosal
barrier injury. Leukemia 2003.
111. Blijlevens NM, Van't Land B, Donnelly JP, M'Rabet L, De Pauw BE. Measuring mucosal
damage induced by cytotoxic therapy. Support Care Cancer 2004.
112. Donnelly JP, De Pauw BE. Voriconazole-a new therapeutic agent with an extended
spectrum of antifungal activity. Clin Microbiol Infect 2004;10 Suppl 1:107-17.
113. Potter M, Donnelly JP. The role of itraconazole in preventing and treating systemic fungal
infections in immunocompromised patients. Acta Haematol 2004;111(3):175-80.
114. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives
on cancer therapy-induced mucosal injury. Cancer 2004;100(9 Suppl):1995-2025.
115. van't Land B, Blijlevens NM, Marteijn J, Timal S, Donnelly JP, de Witte TJ, et al. Role of
curcumin and the inhibition of NF-kappaB in the onset of chemotherapy-induced mucosal
barrier injury. Leukemia 2004;18(2):276-84.
116. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for
the diagnosis and management of invasive aspergillosis. Lancet Infect Dis. 2004 Jun;4(6):349-
57.
117. Blijlevens NM, Lutgens LC, Schattenberg AV, Donnelly JP. Citrulline: a potentially simple
quantitative marker of intestinal epithelial damage following myeloablative therapy. Bone Marrow
Transplant. 2004 Aug;34(3):193-6.
118. Donnelly JP. Defining the place of novel antifungal agents in current clinical practice: a review of
trial data and a discussion of the evidence for efficacy and effectiveness of new triazoles and candins.
In: Prentice AG, Rogers T, Miles A, editors. The effective prevention and management of systemic
fungal infection: Aesculapius Medical Press; 2004. p. 101-16.
119. Levenga H, Donnelly P, Blijlevens N, Verweij P, Shirango H, de Pauw B. Fatal hemorrhagic
pneumonia caused by infection due to Kytococcus sedentarius--a pathogen or passenger? Ann
Hematol. 2004 Jul;83(7):447-9.
120. Verweij PE, Klont RR, Donnelly JP. Validating PCR for detecting invasive aspergillosis. Br J
Haematol. 2004 Oct;127(2):235-6.
121. Lutgens LC, Blijlevens NM, Deutz NE, Donnelly JP, Lambin P, de Pauw BE. Monitoring
myeloablative therapy-induced small bowel toxicity by serum citrulline concentration. Cancer. 2004
Nov 30.
122. Ariano RE, Nyhlen A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA. Pharmacokinetics and
pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother
2005;39(1):32-8.
123. Lutgens LC, Blijlevens NM, Deutz NE, Donnelly JP, Lambin P, de Pauw BE. Monitoring
myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison
with sugar permeability tests. Cancer 2005;103(1):191-9.
124. Blijlevens NM, Donnelly JP, de Pauw BE. Prospective evaluation of gut mucosal barrier injury
following various myeloablative regimens for haematopoietic stem cell transplant. Bone Marrow
Transplant 2005.
125. Blijlevens NM, Donnelly JP, Naber AH, Schattenberg AV, Depauw BE. A randomised, doubleblinded,
placebo-controlled, pilot study of parenteral glutamine for allogeneic stem cell transplant
CV Donnelly
27
patients. Support Care Cancer 2005.
126. Verweij PE, Donnelly JP, van Die CE, Blijlevens NM, Kullberg BJ, de Pauw BE. [Improved
diagnostics in invasive aspergillosis and systematic monitoring in patients at high risk of infection].
Ned Tijdschr Geneeskd 2005;149(11):561-7.
127. Blijlevens NM, Donnelly JP, Depauw BE. Inflammatory response to mucosal barrier injury after
myeloablative therapy in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2005.
128. Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but
still a ways to go. Clin Infect Dis 2006;42(4):487-9.
129. Potting CM, Blijlevens NA, Donnelly JP, Feuth T, Van Achterberg T. A scoring system for the
assessment of oral mucositis in daily nursing practice. Eur J Cancer Care (Engl) 2006;15(3):228-34.
130. Klont RR, Mennink-Kersten MA, Ruegebrink D, et al. Paradoxical increase in circulating Aspergillus
antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis
2006;43(3):e23-5.
131. van der Velden WJ, Blijlevens NM, Klont RR, Donnelly JP, Verweij PE. Primary hepatic invasive
aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative
disorder. Ann Hematol 2006;85(9):621-3.
132. Anaissie EJ, Segal BH, Graybill JR, et al. Clinical research in the lay press: irresponsible journalism
raises a huge dose of doubt. Clin Infect Dis 2006;43(8):1031-9.
133. Hendriks MP, Blijlevens NM, Schattenberg AV, Burger DM, Donnelly JP. Cyclosporine short
infusion and C2 monitoring in haematopoietic stem cell transplant recipients. Bone Marrow Transplant
2006;38(7):521-5.
134. Rodriguez-Tudela JL, Donnelly JP, Pfaller MA, et al. Statistical analyses of correlation for
fluconazole minimal inhibitory concentrations and Candida spp. for standard methodologies of EUCAST
(E.Dis. 7.1) and CLSI (M27 A2). J Clin Microbiol 2006;45(1):109-11.
135. Mouton JW, van Peer A, de Beule K, Van Vliet A, Donnelly JP, Soons PA. Pharmacokinetics of
itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel
formulation. Antimicrob Agents Chemother 2006;50(12):4096-102.
136. Blijlevens NM, Donnelly JP, Yakar D, van Die CE, de Witte T. Determining mucosal barrier injury
to the oesophagus using CT scan. Support Care Cancer 2007.
137. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis--has the principle been proven? N Engl J
Med 2007;356(4):409-11.
138. Rodriguez-Tudela JL, Donnelly JP, Pfaller MA, et al. Statistical Analyses of Correlation between
Fluconazole MICs for Candida spp. Assessed by Standard Methods Set Forth by the European
Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). J Clin Microbiol
2007;45(1):109-11.
139. Maertens JA, Klont R, Masson C, et al. Optimization of the cutoff value for the Aspergillus doublesandwich
enzyme immunoassay. Clin Infect Dis 2007;44:1329-36.
CV Donnelly
28
Book chapters
1. Donnelly JP, ed. Serum bactericidal levels in leukaemic patients treated with either netilmicin or
tobramycin in combination with mezlocillin and cefuroxime; 1982.
2 De Pauw BE, Donnelly JP, Harding I. Clinical experience with teicoplanin in patients with
intravascular line infection due to Gram-positive bacteria. In: Phillips I, ed. Focus on coagulasenegative
staphylococci. London: Royal Society of Medicine; 1989:107-18.
3 Donnelly JP. Colistin. In: Dollery CT, ed. Therapeutic Drugs. Edinburgh, London, Melbourne, New
York, Tokyo and Madrid: Churchill Livingstone; 1991.
4 Donnelly JP. Chemoprophylaxis for the prevention of bacterial and fungal infections. In: Klastersky
J, ed. Infectious complications of cancer. Boston, Dordrecht, London: Kluwer Academic Publishers;
1995:45-81.
5 De Pauw BE, Donnelly JP, Kullberg BJ. Host impairments in patients with neoplastic diseases. In:
Noskin GA, ed. Management of infectious complication in cancer patients. Boston: Kluwer Academic
Publishers; 1998:1-32.
6 Donnelly JP. Miconazole. In: Dollery CT, ed. Therapeutic Drugs. 2 nd ed. Edinburgh, London,
Melbourne, New York, Tokyo and Madrid: Churchill Livingstone; 1998.
7 De Pauw BE, Donnelly JP. Infections in the Immunocompromised Host: General Principles. In:
Mandell GL, Douglas RG, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and
practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000:3079-90.
8 Donnelly JP. Infection in bone marrow transplant patients. In: Thiru S, Waldmaan H, eds.
Pathology and Immunology of transplantation and Rejection. Oxford: Blackwell Science Ltd;
2001:526-66.
9 Donnelly JP. Prophylaxis of infections. In: Rolston KVI, Rubenstein EB, eds. Textbook of febrile
nutropenia. London: Martin Dunnitz Ltd; 2001:215-43.
10 Donnelly JP. Future perspectives in management of systemic fungal infection: review of recent,
ongoing and planned trials and the need for a national survveillance and audit of infection. In:
Prentice AG, Rogers T, Miles A, eds. The effective prevention and management of systemic fungal
infection in haematological malignancy. London, San Francisco, Sydney: Aesculapius Medical Press;
2001:133-49.
11 Donnelly JP. Defining the place of novel antifungal agents in current clinical practice: a review of
trial data and a discussion of the evidence for efficacy and effectiveness of new triazoles and
candins. In: Prentice AG, Rogers T, Miles A, eds. The effective prevention and management of
systemic fungal infection: Aesculapius Medical Press; 2004:101-16.
12 Donnelly JP, De Pauw BE. Infections in the Immunocompromised Host: General Principles. 6th Ed.
ed. Philadelphia: Elsevier/Churchill Livingstone; 2005.
CV Donnelly
29
13 Prentice AG, Donnelly JP. Supportive care in the management of leukaemia. In: Hoffbrand V,
Tuddenham E, Catovsky D, eds. Postrgraduate Haematology. 5th ed. London: Blackwell Publishing;
2005:598-604.
14 Mandell GL, Bennett JE, Dolin R. Mandell, Douglas and Bennett's principles and practice of infectious
diseases. 5th ed. / edited by Gerald L. Mandell, John E. Bennett, Raphael Dolin. ed. [Philadelphia ;
London]: Churchill Livingstone; 2000.
15 Donnelly JP. Framycetin. In: Dollery CT, ed. Therapeutic Drugs. Edinburgh, London, Melbourne,
New York, Tokyo and Madrid: Churchill Livingstone; 1991.
CV Donnelly
30
Other contributions
1. De Pauw B E, Novàkovà I R O, Donnelly J.P, Horrevorts A. Mono- of combinatietherapie bij
ernstige bacteriële infecties? Ned.T.Geneesk. 1989;133:954-5.
2. Donnelly JP Ceftazidime as first-line therapy for fever in neutropenic patients with acute
leukaemia Perspectives on Therapeutics 1984
3. Donnelly JP, Worsley AM, Marcus RE et al Empiric therapy in cancer patients: monotherapy
versus triple-drug therapy Infekt Tumor 1985 München
4. Donnelly JP, Starke ID, Irving W Infection and the Immunocompromised Host Ed Geddes AM
1985 Curr Med Lit
5. Donnelly JP Possibilities and limitations of modern antimicrobial therapy: the neutropenic
patient Antibiotika Dialog 1985
6. Donnelly JP Ceftazidime - is it effective as monotherapy for infection in the neutropenic
patient? Perspectives on Therapeutics 1985
7. Donnelly JP Ceftazidime versus combination treatment for the treatment of infection in
neutropenic patients Perspectives on Therapeutics 1986
8. Starke ID, Donnelly JP, Finch R (Ed) Antimicrobial therapy in the immunocompromised
patient Part 1 Patient Recognition 1986 Curr Med Lit
9. Starke ID, Donnelly JP, Finch R (Ed) Antimicrobial therapy in the immunocompromised
patient Part 2 Antimicrobial agents 1988 Curr Med Lit
10. Starke ID, Donnelly JP, Finch R (Ed) Antimicrobial therapy in the immunocompromised
patient Part 3: Rational treatment of infection in the immunocompromised Patient 1992 Curr
Med Lit